5-[1,1-Dimethyl-5-(5-methyl-5-tetrazol-5-yl-hexane-1-sulfanyl)-pentyl]-1H-tetrazole | 412935-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-[1,1-Dimethyl-5-(5-methyl-5-tetrazol-5-yl-hexane-1-sulfanyl)-pentyl]-1H-tetrazole
• 英文别名: 5-[2-methyl-6-[5-methyl-5-(2H-tetrazol-5-yl)hexyl]sulfanylhexan-2-yl]-2H-tetrazole
• CAS: 412935-48-9
• 化学式: C₁₆H₃₀N₈S
• 分子量: 366.534
• InChiKey: PMHVXVBFTQQYCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Sulfide and disulfide compounds and compositions for cholesterol management and related uses
  申请人：——

  公开号：US20020077316A1

  公开（公告）日：2002-06-20

  The present invention relates to novel sulfide and disulfide compounds, compositions comprising sulfide and disulfide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型硫化物和二硫化物化合物，含有硫化物和二硫化物化合物的组合物，以及使用含有醚化合物的组合物治疗和预防心血管疾病、血脂异常、蛋白异常和葡萄糖代谢紊乱的方法。本发明的化合物、组合物和方法也可用于治疗和预防阿尔茨海默病、X综合症、过氧化物酶体增殖物激活受体相关疾病、败血症、血栓性疾病、肥胖症、胰腺炎、高血压、肾脏疾病、癌症、炎症和阳痿。在某些实施例中，本发明的化合物、组合物和方法与其他治疗剂，如降胆固醇和降血糖药物一起进行联合治疗。
• CHEMICAL COMPOUNDS
  申请人：Astrazeneca AB

  公开号：EP1412362A1

  公开（公告）日：2004-04-28
• US6703422B2
  申请人：——

  公开号：US6703422B2

  公开（公告）日：2004-03-09
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2003008422A1

  公开（公告）日：2003-01-30

  The invention relates to a compound of formula (1)(A chemical formula should be inserted here - please see paper copy enclosed) wherein Q is -CO- or -C(R4)(R5)- (wherein R4 is a hydrogen atom or C¿1-4?alkyl and R?5¿ is a hydrogen atom or hydroxy group) and Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease.